Cancer
Conditions
Brief summary
The aim of this study is to evaluate the Turkish validity and reliability of the Patient Reported Outcomes for Fighting Financial Toxicity of Cancer (PROFFIT) developed in Italy.
Detailed description
The scale validity of the study will be evaluated through language and content validity, construct validity, criterion validity, and known-group validity methods; while the scale reliability will be assessed by calculating the Cronbach's alpha and McDonald's omega reliability coefficients.
Interventions
None listed
Sponsors
Giresun Training and Research Hospital
St. Mary's University, Twickenham
Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale
Akdeniz University
Study design
Observational model
OTHER
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Individuals diagnosed with solid cancer or hematologic malignancy, either histologically or cytologically, and aware of their diagnosis, * Those who have received cancer treatment (chemotherapy, targeted therapy, immunotherapy, hormonal therapy, radiotherapy, or a combination of these treatments) within the last three months, * Individuals over the age of 18, * Those without a diagnosed psychiatric illness (such as depression, panic attacks, schizophrenia, etc.), * Individuals without auditory or cognitive impairments, * Turkish-speaking and literate volunteers.
Exclusion criteria
* Individuals who fill out the data collection forms incompletely or wish to withdraw from the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Validity Assessment-Language and Content Validity | Through study completion, an average of 12 months | Language and Content Validity: To assess the relevance and appropriateness of the translated items, a panel of at least six experts in oncology, psychology, and instrument development will evaluate each item. |
| Validity Assessment-Content Validity Index (CVI) | Through study completion, an average of 12 months | Content Validity Index (CVI) will be calculated based on expert ratings to determine the proportion of items deemed relevant. |
| Validity Assessment-Content Validity Ratio (CVR) | Through study completion, an average of 12 months | Content Validity Ratio (CVR) will be used to assess whether each item is essential for measuring the construct. |
| Validity Assessment-Construct Validity | Through study completion, an average of 12 months | Confirmatory Factor Analysis (CFA) will be performed to verify whether the factor structure of the Turkish version aligns with that of the original instrument. Model fit indices such as χ²/df, RMSEA, CFI, TLI, and SRMR will be used to evaluate the adequacy of the factor structure. |
| Validity Assessment- Criterion Validity | Through study completion, an average of 12 months | The Turkish PROFFIT scores will be correlated with other established patient-reported outcome measures, specifically the COST (v2) and EORTC QLQ-C30 instruments, to assess convergent validity. Pearson or Spearman correlation coefficients will be used to determine the strength of associations between PROFFIT and these validated measures. |
| Validity Assessment- Known-Group Validity | Through study completion, an average of 12 months | To assess whether the instrument can differentiate between groups with known differences in financial toxicity, mean scores of the total and subscales will be compared across predefined demographic and clinical groups. Independent samples t-tests and ANOVA will be performed to compare group differences. |
| Reliability Assessment | Through study completion, an average of 12 months | Internal Consistency: The reliability of the Turkish PROFFIT instrument will be evaluated using: Cronbach's alpha (α) to assess the overall internal consistency of the scale. McDonald's omega (ω) as an alternative measure that provides a more robust estimation of reliability in multidimensional scales. |
Contacts
Primary ContactZeynep Karakuş, PhD
Backup ContactZeynep Özer, PhD
Outcome results
None listed